---
schema_version: "secwatch.filing_event.v1"
accession: "0001860742-25-000016"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:11:38.142700+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb Q2 revenue $1.278B, GAAP loss narrows to $62M, raises FY2025 guide

## Summary
- Revenue $1.278B, +5% as reported (+3% constant currency); Vision Care +8%, Surgical +3%, Pharma flat.
- GAAP net loss $62M ($0.18 loss per share) vs $151M loss ($0.43) a year ago; adjusted net income $25M ($0.07 adjusted EPS).
- Adjusted EBITDA $191M vs $209M prior year; Adj EBITDA ex-IPR&D $192M vs $212M.
- Raised FY2025 guidance: revenue $5.05B-$5.15B (prior $5.0B-$5.1B), constant currency growth ~5-7%; Adj EBITDA ex-IPR&D $860M-$910M.
- Resumed full production of enVista IOLs following recall; dry eye portfolio reached ~$1B trailing revenue.

## SEC filing metadata
- accession: 0001860742-25-000016
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000186074225000016/0001860742-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000186074225000016/blco-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860742-25-000016
- JSON: https://secwatch.observer/filing/0001860742-25-000016.json
- Plain text: https://secwatch.observer/filing/0001860742-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.